FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892684519> ?p ?o ?g. }

• W2892684519 abstract "Humanity has become largely dependent on artemisinin derivatives for both the treatment and control of malaria, with few alternatives available. A Plasmodium falciparum phenotype with delayed parasite clearance during artemisinin-based combination therapy has established in Southeast Asia, and is emerging elsewhere. Therefore, we must know how fast, and by how much, artemisinin-resistance can strengthen. P. falciparum was subjected to discontinuous in vivo artemisinin drug pressure by capitalizing on a novel model that allows for long-lasting, high-parasite loads. Intravenous artesunate was administered, using either single flash-doses or a 2-day regimen, to P. falciparum-infected humanized NOD/SCID IL-2Rγ−/−immunocompromised mice, with progressive dose increments as parasites recovered. The parasite’s response to artemisinins and other available anti-malarial compounds was characterized in vivo and in vitro. Artemisinin resistance evolved very rapidly up to extreme, near-lethal doses of artesunate (240 mg/kg), an increase of > 3000-fold in the effective in vivo dose, far above resistance levels reported from the field. Artemisinin resistance selection was reproducible, occurring in 80% and 41% of mice treated with flash-dose and 2-day regimens, respectively, and the resistance phenotype was stable. Measuring in vitro sensitivity proved inappropriate as an early marker of resistance, as IC50 remained stable despite in vivo resistance up to 30 mg/kg (ART-S: 10.7 nM (95% CI 10.2–11.2) vs. ART-R30: 11.5 nM (6.6–16.9), F = 0.525, p = 0.47). However, when in vivo resistance strengthened further, IC50 increased 10-fold (ART-R240 100.3 nM (92.9–118.4), F = 304.8, p < 0.0001), reaching a level much higher than ever seen in clinical samples. Artemisinin resistance in this African P. falciparum strain was not associated with mutations in kelch-13, casting doubt over the universality of this genetic marker for resistance screening. Remarkably, despite exclusive exposure to artesunate, full resistance to quinine, the only other drug sufficiently fast-acting to deal with severe malaria, evolved independently in two parasite lines exposed to different artesunate regimens in vivo, and was confirmed in vitro. P. falciparum has the potential to evolve extreme artemisinin resistance and more complex patterns of multidrug resistance than anticipated. If resistance in the field continues to advance along this trajectory, we will be left with a limited choice of suboptimal treatments for acute malaria, and no satisfactory option for severe malaria." @default.
• W2892684519 created "2018-10-05" @default.
• W2892684519 creator A5014858344 @default.
• W2892684519 creator A5027266939 @default.
• W2892684519 creator A5036135449 @default.
• W2892684519 creator A5047042318 @default.
• W2892684519 creator A5054185332 @default.
• W2892684519 creator A5060483993 @default.
• W2892684519 creator A5062237693 @default.
• W2892684519 creator A5066529555 @default.
• W2892684519 creator A5068290984 @default.
• W2892684519 date "2018-10-01" @default.
• W2892684519 modified "2023-10-15" @default.
• W2892684519 title "High-level artemisinin-resistance with quinine co-resistance emerges in P. falciparum malaria under in vivo artesunate pressure" @default.
• W2892684519 cites W1544864283 @default.
• W2892684519 cites W1969571661 @default.
• W2892684519 cites W1972177048 @default.
• W2892684519 cites W1975192103 @default.
• W2892684519 cites W1983776399 @default.
• W2892684519 cites W1990392794 @default.
• W2892684519 cites W1993347313 @default.
• W2892684519 cites W1993775596 @default.
• W2892684519 cites W2002469675 @default.
• W2892684519 cites W2010067521 @default.
• W2892684519 cites W2014613515 @default.
• W2892684519 cites W2019105064 @default.
• W2892684519 cites W2020251171 @default.
• W2892684519 cites W2020465799 @default.
• W2892684519 cites W2023818253 @default.
• W2892684519 cites W2035758606 @default.
• W2892684519 cites W2035826427 @default.
• W2892684519 cites W2040713555 @default.
• W2892684519 cites W2048404226 @default.
• W2892684519 cites W2048883882 @default.
• W2892684519 cites W2049016946 @default.
• W2892684519 cites W2051532180 @default.
• W2892684519 cites W2051695178 @default.
• W2892684519 cites W2055730063 @default.
• W2892684519 cites W2061516190 @default.
• W2892684519 cites W2062905495 @default.
• W2892684519 cites W2064110684 @default.
• W2892684519 cites W2067559517 @default.
• W2892684519 cites W2073150510 @default.
• W2892684519 cites W2076029682 @default.
• W2892684519 cites W2081078606 @default.
• W2892684519 cites W2087956351 @default.
• W2892684519 cites W2094472381 @default.
• W2892684519 cites W2096029903 @default.
• W2892684519 cites W2096267252 @default.
• W2892684519 cites W2097205415 @default.
• W2892684519 cites W2097263871 @default.
• W2892684519 cites W2104700616 @default.
• W2892684519 cites W2105668259 @default.
• W2892684519 cites W2116792616 @default.
• W2892684519 cites W2116975743 @default.
• W2892684519 cites W2119156545 @default.
• W2892684519 cites W2123030025 @default.
• W2892684519 cites W2123640851 @default.
• W2892684519 cites W2124634096 @default.
• W2892684519 cites W2125265260 @default.
• W2892684519 cites W2125397010 @default.
• W2892684519 cites W2129428401 @default.
• W2892684519 cites W2132093894 @default.
• W2892684519 cites W2135926190 @default.
• W2892684519 cites W2137529385 @default.
• W2892684519 cites W2138717517 @default.
• W2892684519 cites W2139324809 @default.
• W2892684519 cites W2151141738 @default.
• W2892684519 cites W2151314542 @default.
• W2892684519 cites W2161051245 @default.
• W2892684519 cites W2161311583 @default.
• W2892684519 cites W2164108601 @default.
• W2892684519 cites W2165789743 @default.
• W2892684519 cites W2166369726 @default.
• W2892684519 cites W2168987526 @default.
• W2892684519 cites W2171102256 @default.
• W2892684519 cites W2171182913 @default.
• W2892684519 cites W2172020091 @default.
• W2892684519 cites W2187295707 @default.
• W2892684519 cites W2191590274 @default.
• W2892684519 cites W2234562695 @default.
• W2892684519 cites W2314845920 @default.
• W2892684519 cites W2338020438 @default.
• W2892684519 cites W2467259677 @default.
• W2892684519 cites W2528949466 @default.
• W2892684519 cites W2599428094 @default.
• W2892684519 cites W2606281194 @default.
• W2892684519 cites W2739407490 @default.
• W2892684519 cites W2755621348 @default.
• W2892684519 cites W2793098970 @default.
• W2892684519 doi "https://doi.org/10.1186/s12916-018-1156-x" @default.
• W2892684519 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6166299" @default.
• W2892684519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30269689" @default.
• W2892684519 hasPublicationYear "2018" @default.
• W2892684519 type Work @default.
• W2892684519 sameAs 2892684519 @default.
• W2892684519 citedByCount "22" @default.
• W2892684519 countsByYear W28926845192018 @default.
• W2892684519 countsByYear W28926845192019 @default.
• W2892684519 countsByYear W28926845192020 @default.

• next